Join
Live feed
·
PRReleasevia Quantisnow
Qiagen N.V. logo

QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook

ByQuantisnow·Wall Street's wire, on your screen.
QGEN· Qiagen N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track QGEN (Qiagen N.V.) and more on Quantisnow.